YIVIVA, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- https://yiviva.com
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
Phase 2
Completed
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Drug: Sorafenib+YIV-906Drug: Sorafenib+placebo
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Yiviva Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT04000737
- Locations
- 🇺🇸
Calvin Pan. MD Gastroenterology & Hepatology Clinic, Flushing, New York, United States
🇺🇸Northwell Monter Cancer Institute, Lake Success, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
News
No news found